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Summary  Numerous  reports  have  shown  an  unquestionable  association  between  ﬁbrotic  valve
disease and  the  following  drugs:  ergot  alkaloids  (such  as  methysergide  and  ergotamine),  ergot-
derived dopaminergic  agonists  (such  as  pergolide  and  cabergoline)  and  drugs  metabolized  into
norfenﬂuramine  (such  as  fenﬂuramine,  dexfenﬂuramine  and  benﬂuorex).  This  review  focuses
on different  aspects  of  drug-induced  valvular  heart  disease:  historical  background;  echocar-
diographic  features;  different  drugs  recognized  as  being  responsible  for  valvular  heart  disease;
and pathophysiology.
©  2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  Il  est  maintenant  bien  établi  que  le  développement  d’un  processus  ﬁbrotique  au
niveau des  valves  cardiaques  peut  être  associé  à  l’utilisation  des  médicaments  suivants  :
alcaloïdes de  l’ergot  comme  méthysergide  et  ergotamine,  agonistes  dopaminergiques  égale-
ment dérivés  de  l’ergot  ainsi  que  des  médicaments  dont  le  point  commun  est  qu’ils  sontDérivés  d’ergot  ;
Norfenﬂuramine  ;
métabolisés  en  norfenﬂuramine,  la  ﬂenﬂuramine,  la  dexfenﬂuramine  et  le  benﬂuorex.  Cette
revue générale  concerne  différents  aspects  de  ces  valvulopathies  médicamenteuses  :  historique,Régurgitation caractéristiques  échocardiographiques,  principales  substances  concernées  et  mécanismes  phys-
valvulaire  ;
Valvulopathies
médicamenteuses
iopathologiques.
© 2013  Elsevier  Masson  SAS.  Tou
Abbreviations: BMI, body mass index; CI, conﬁdence interval; FDA,
Database; MDMA, 3,4-methylenedioxymethamphetamine; VHD, valvular 
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Figure 1. Patient with toxic aortic and mitral valvulopathy due to
benﬂuorex. On this apical four-chamber view using two-dimensional
echocardiography, the mitral leaﬂets have lost their ﬂexibility. Note
the marked remodelling of the mitral subvalvular apparatus, with
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ackground
he  possibility  that  the  intake  of  drugs  might  be  respon-
ible  for  the  onset  of  valvular  heart  disease  (VHD)  was
rst  proposed  in  the  mid-1960s  for  ergot  alkaloids  used
or  migraine  prophylaxis  —  initially  methysergide  (Desernil®)
nd  then  ergotamine  (Gynergene®).  In  1997  to  1998,
rug-related  VHD  was  reported  for  two  appetite  sup-
ressants  —  fenﬂuramine  (Ponderal®)  and  dexfenﬂuramine
Isomeride®)  —  that  had  previously  been  recognized  as
eing  associated  with  the  occurrence  of  pulmonary  arte-
ial  hypertension.  These  ﬁndings  led  to  the  withdrawal
rom  the  market  of  these  two  drugs.  More  recently,
imilar  ﬁndings  of  drug-related  VHD  with  ergot-derived
opamine  agonists  were  reported  in  patients  treated
ith  pergolide  (Celance®)  for  Parkinson’s  disease  and
abergoline  (Dostinex®)  for  hyperprolactinaemic  disorders.
ubsequently,  similar  drug-related  VHD  was  reported  with
rolonged  use  of  the  recreational  drug  ecstasy  (3,4-
ethylenedioxymethamphetamine;  MDMA)  and  with  a  drug
ndicated  for  diabetes  in  overweight  patients  (benﬂuorex;
ediator®).  The  diagnosis  of  such  drug-related  VHD  is  based
n  echocardiography.
All  of  these  drugs  that  have  been  shown  to  be  capable
f  inducing  VHD  were  found  to  have  a  common  pharmaco-
ogical  action  on  a  speciﬁc  serotonin  receptor  —  the  5HT2B
eceptor.  Indeed,  these  drugs  have  an  agonistic  action,  with
 high  afﬁnity  for  these  receptors  (which  are  highly  present
n  valvular  tissue),  leading  to  valvular  alterations  similar
o  those  observed  previously  in  carcinoid  heart  disease,
 neuroendocrine  malignancy  linked  to  enterochromafﬁn
ells,  which  produce  great  quantities  of  serotonin.  The
arious  drug-induced  VHDs  have  similar  morphological  and
istological  features,  characterized  by  tissue  thickening
nd  an  abundant  extracellular  matrix  of  glycosaminogly-
ans  and  collagen,  with  proliferation  of  myoﬁbroblasts  and
mooth  muscle  cells,  few  calciﬁcations  and  no  pronounced
nﬂammation.  The  underlying  valve  structure  is  usually
nchanged.
chocardiographic features
chocardiography  is  the  key  examination  for  screening  and
rading  iatrogenic  valve  disease  [1].  The  echocardiographic
eatures  are  common  for  all  drug-induced  VHDs.  Variable
egrees  of  valve  regurgitation  are  observed.  Drug-induced
alve  disease  is  generally  not  responsible  for  severe  valve
tenosis.  It  can  be  difﬁcult  to  attribute  a  causal  relation-
hip  between  a  speciﬁc  drug  and  valve  damage  because
retreatment  echocardiographic  data  are  not  available  in
he  majority  of  cases.  Moreover,  mere  detection  of  regur-
itation  does  not  provide  information  on  the  aetiology.
ctually,  diagnosis  using  two-dimensional  echocardiography
s  based,  above  all,  on  studying  the  texture  and  motion
f  the  valves  and  analysing  the  subvalvular  apparatus  for
itral  and  tricuspid  VHD.  Typically,  one  can  generally  see
ild  or  moderate  valve  thickening  in  the  absence  of  cal-
iﬁcation  or  marked  commissural  fusion  (in  contrast  with
heumatic  valve  disease).  Restricted  valve  motion,  which
s  responsible  for  the  regurgitation,  is  the  most  charac-
eristic  feature  of  drug-induced  valve  disease.  In  mitral
F
t
clight thickening of both leaﬂets.
alve  regurgitation,  the  restriction  generally  affects  both
itral  leaﬂets  but  often  predominates  at  the  posterior
eaﬂet.  Leaﬂet  thickening  is  often  minimal  but  is  gener-
lly  associated  with  unequivocal  thickening  and  shortening
f  the  chordae  tendineae  (Figs.  1  and  2).  In  aortic  regur-
itation,  valve  thickening  is  often  mild  (and  may  not
e  present).  Variable  degrees  of  leaﬂet  retraction  are
bserved,  responsible  for  malcoaptation  and  regurgitation
uring  diastole  (Fig.  1).  Using  two-dimensional  echocar-
iography,  a  small  central  triangular  valve  hiatus  during
iastole  is  observed  in  the  short-axis  view,  sometimes  asso-
iated  with  a  subtle  ‘dome-like’  aspect  of  the  aortic  valve
uring  systole.  Aortic  regurgitation  visualized  with  colour
oppler  is  generally  central.  Tricuspid  and  pulmonary  drug-
nduced  VHD  is  less  common;  echocardiographic  ﬁndings
eem  similar  to  those  observed  in  mitral  and  aortic  dam-
ge.igure 2. Same patient as in Fig. 1: the aortic cusps are slightly
hickened, restrictive and ﬁbrous-looking, with defective central
oaptation.
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VDrug-induced  valvular  heart  disease  
Valvular heart disease associated with
migraine drugs
Methysergide  and  ergotamine  are  old  drugs  used  to  prevent
or  treat  migraine.  These  drugs  were  the  ﬁrst  to  be  recog-
nized  as  being  associated  potentially  with  the  occurrence
of  valvular  regurgitation.  Methysergide  —  already  known  to
induce  ﬁbrotic  tissue  alterations,  which  may  explain  pul-
monary  arterial  hypertension  as  well  as  retroperitoneal
ﬁbrosis  —  was  the  ﬁrst  drug  to  be  implicated.  In  1967,
Graham  et  al.  [2]  associated  the  development  of  valvular
abnormalities  with  the  use  of  this  drug.  Indeed,  they  pub-
lished  a  series  of  36  patients  treated  on  a  long-term  basis
with  methysergide,  who  developed  cardiac  murmurs  linked
to  mitral  and/or  aortic  regurgitation  (generally  without  clin-
ical  symptoms),  with  regression  or  disappearance  of  the
murmurs  after  drug  discontinuation  in  more  than  one  third  of
patients.  Some  years  later,  a  frequently-associated  involve-
ment  of  the  tricuspid  valves  was  highlighted  [3]. Then,
in  1974,  ergotamine  —  another  ergot  alkaloid  structurally
related  to  methysergide  —  was  also  shown  to  be  associ-
ated  with  left-sided  VHD  for  the  ﬁrst  time,  with  other  cases
reported  thereafter.  From  1974,  the  ﬁbrotic  nature  of  the
valvular  lesions  was  recognized,  with  an  emphasis  on  these
lesions  being  morphologically  similar  to  those  described  in
carcinoid  heart  disease  [1,4].  These  drugs  are  still  on  the
market  but  are  used  only  for  short-term  treatment  and  very
rarely  induce  VHD.
Valvular heart disease associated with
fenﬂuramine and dexfenﬂuramine
VHDs  have  been  observed  with  fenﬂuramine  and  dexfen-
ﬂuramine,  which  were  used  largely  as  anti-obesity  drugs.
A  short  time  after  the  withdrawal  of  these  drugs  from  the
market  in  France,  due  to  the  demonstration  that  they  may
induce  pulmonary  arterial  hypertension  [5],  the  ﬁrst  24  cases
of  valvular  insufﬁciencies  were  reported  in  the  USA  with
the  fenﬂuramine-phentermine  association,  in  women  aged
44  ±  8  years  [6].  These  patients  were  known  to  have  no
past  cardiovascular  history  and  took  this  drug  combination
for  a  mean  duration  of  12  months;  they  presented  with
cardiac  failure  symptoms  or  a  heart  murmur.  Echocardio-
grams  performed  on  these  patients  demonstrated  an  unusual
valvular  morphology,  with  varying  degrees  of  valvular  regur-
gitation  involving  both  left-  and  right-sided  valves.  The
involved  valves  exhibited  leaﬂet  thickening,  with  retraction
of  the  chordae  tendineae  leading  to  malcoaptation  of  the
valves  and  regurgitation.  Five  of  the  patients  subsequently
underwent  cardiac  surgery  for  valve  replacement.  The
histopathological  features  of  the  valves  excised  were  nearly
identical  to  those  seen  in  patients  with  carcinoid  syndrome
and  those  previously  described  with  ergot  alkaloid-related
antimigraine  drugs  (plaques  of  proliferative  myoﬁbroblasts
in  an  abundant  extracellular  myxoid  or  collagen  matrix).
After  this  ﬁrst  publication,  the  Food  and  Drug  Administration
(FDA)  indicated  that  a  signiﬁcant  number  of  VHD  notiﬁca-
tions  had  been  received  in  association  with  the  intake  of
phentermine  in  combination  with  fenﬂuramine  as  well  as
b
B
b335
ith  dexfenﬂuramine  (approved  for  use  in  the  USA  in  1996).
hirty-three  cases  were  indeed  retrieved  by  notiﬁcations.
Other  studies  were  published  some  months  later,  showing
hat  duration  of  drug  exposure  played  a  signiﬁcant  role  in  the
evelopment  of  VHD.  Thus,  in  the  study  performed  by  Khan
t  al.  [7],  it  was  found  that  prolonged  intake  of  fenﬂuramine
r  dexfenﬂuramine  led  to  a  multiplication  of  the  risk  of  VHD
y  22.  Data  other  than  from  the  USA  were  published  with
oncordant  results.  Thus,  Jick  et  al.  [8]  retrospectively  ana-
ysed  the  UK  General  Practice  Research  Database  (GPRD)  and
xtracted  symptomatic  cases  of  VHD  conﬁrmed  by  echocar-
iography  and  associated  with  the  intake  of  fenﬂuramine
r  dexfenﬂuramine  (duration  of  treatment  21  ±  12  months)
ut  no  cases  associated  with  phentermine  alone  or  obese
atients  who  did  not  take  appetite  suppressants.  This  was
n  important  consideration,  as  a  hypothesis  regarding  a  spe-
iﬁc  potential  role  for  obesity  itself  in  the  development  of
HD  had  been  advanced.  The  5-year  cumulative  incidence
f  valvular  regurgitation  was  found  to  be  7.1  per  10,000
atient-years  when  fenﬂuramine  or  dexfenﬂuramine  was
aken  for  less  than  3  months  and  35  per  10,000  patient-years
or  a  treatment  duration  of  4  months  or  more.
Studies  performed  later  also  took  into  account  the  poten-
ially  confounding  factor  of  obesity  itself  and  the  fact
hat  unexplained  valvular  regurgitations  may  occur  spon-
aneously.  Taking  into  account  these  possible  biases,  all
he  studies  conﬁrmed  the  potential  of  fenﬂuramine  and
exfenﬂuramine  to  induce  valvular  regurgitations  when
dministered  on  a  long-term  basis.  A  meta-analysis  of
ine  published  case-control  pharmacoepidemiological  stud-
es  by  Sachdev  et  al.  [9]  compared  3769  patients  with  5009
atched  controls  (mean  age  46  years;  85%  of  women  with  a
ean  body  mass  index  [BMI]  of  36;  mean  duration  of  treat-
ent  397  days).  When  the  drug  intake  duration  was  greater
han  90  days,  12%  of  patients  presented  VHDs  when  taking
enﬂuramine-type  appetite  suppressants  compared  with  5%
f  obese  patients  who  were  not  taking  these  drugs  (odds
atio  [OR]  2.2;  95%  conﬁdence  interval  [CI]  1.7—2.7).  Thus,
ne  in  eight  patients  receiving  these  drugs  for  greater  than
0  days  was  found  to  have  VHD,  with  aortic  regurgitations
ccurring  three  times  more  frequently  than  mitral  regurgi-
ations.
So,  much  data  reported  in  the  literature  support  the  point
hat  fenﬂuramine-type  appetite  suppressants  may  induce
HD  —  mainly  aortic  regurgitation  but  also,  although  with
 lower  incidence,  mitral  restrictive  regurgitation,  essen-
ially  when  the  duration  of  drug  intake  was  greater  than
 to  6  months  [10], whereas  pulmonary  arterial  hyperten-
ion  may  appear  after  a  shorter  treatment  time.  It  has
een  reported  that  withdrawal  of  the  drugs  decreases  the
everity  of  regurgitation  or  stabilizes  the  valvular  lesions
n  some  of  the  patients  involved  [11].  However,  several
ases  of  fenﬂuramine-associated  valvular  disease  have  been
eported  up  to  7  years  after  drug  withdrawal  [12,13].
alvular heart disease associated with
enﬂuorex (Mediator®)
enﬂuorex  (Mediator®)  is  the  most  recent  drug  found  to
e  involved  in  inducing  VHD.  This  drug  is  structurally
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elated  to  amphetamines  and  is  partially  metabolized  to
orfenﬂuramine.  It  was  initially  indicated  in  patients  with
ypertriglyceridaemia  or  for  diabetes  mellitus  in  overweight
atients  in  combination  with  dietetic  recommendations.  In
rance,  following  reassessment  of  the  beneﬁt—risk  balance
n  patients  with  hypertriglyceridaemia,  the  Medicine  Drug
gency  decided  in  April  2007  to  limit  benﬂuorex  use  to  its
ther  indication,  diabetes  mellitus  in  overweight  patients
BMI  ≥  25  kg/m2)  in  association  with  an  appropriate  diet.
enﬂuorex  had  also  been  widely  prescribed  in  France  as  an
ppetite  suppressant.
The  ﬁrst  case  reports  of  benﬂuorex-associated  VHD
ere  published  successively  in  2003,  2006,  2009  and  2010
14—17].  The  ﬁrst  publication  described  a  case  of  multiple
alve  disease  requiring  mitral  and  aortic  valve  replace-
ent  and  tricuspid  valvuloplasty  [17].  This  case  was  related
o  intermittent  and  short-term  intake  of  benﬂuorex.  The
econd  report  [16]  concerned  severe  mitral  regurgitation
ssociated  with  tricuspid  regurgitation  in  a  woman  who  had
een  treated  with  benﬂuorex  for  8  years.  The  third  case
f  benﬂuorex-associated  valvulopathy  was  associated  with
 series  of  ﬁve  pulmonary  arterial  hypertension  cases  [14].
Subsequently,  two  studies  compared  patients  selected
s  having  ‘unexplained’  mitral  regurgitation  with  age-  and
ex-matched  patients  who  had  mitral  regurgitation  with
etiological  or  functional  explanations  [18,19];  the  lat-
er  patients  were  used  as  the  control  group.  In  the  ﬁrst
tudy,  performed  by  Frachon  et  al.  [18],  27  patients  with
nexplained  mitral  regurgitation  were  compared  with  54
ontrols.  The  use  of  benﬂuorex  was  documented  in  19
atients  in  the  ﬁrst  group  and  in  three  in  the  second  group,
ith  an  odds  ratio  of  17.1  (3.5—83)  after  adjustment  for
MI,  diabetes  and  dexfenﬂuramine  intake.  In  a  second  study
onﬁrming  these  results  [19],  22  patients  with  unexplained
itral  regurgitation  were  compared  with  22  of  156  patients
ho  underwent  surgery  for  dystrophic  mitral  regurgitation,
atched  for  age,  body  weight  and  diabetes.  Eight  of  the
2  patients  (36.4%)  in  the  ﬁrst  group  but  only  one  (4.5%)
n  the  group  with  dystrophic  valvulopathy  had  a  history
f  benﬂuorex  use.  The  total  duration  of  benﬂuorex  treat-
ent  associated  with  unexplained  mitral  regurgitation  was
3  (12—175)  months;  the  duration  of  benﬂuorex  treatment
as  56  months  at  the  time  of  valvular  disease  diagnosis.
More  recently,  40  cases  identiﬁed  retrospectively  in
he  cardiology  departments  in  eight  hospitals  in  France
ave  been  reported  and  analysed  [20].  Owing  to  hospi-
al  recruitment  of  symptomatic  patients,  the  observations
ollected  represent  the  most  severe  presentation  of  these
HDs.  The  cases  analysed  in  this  multicentre  registry  had
 quite  homogeneous  presentation:  patients  were  middle-
ged  and  mainly  women,  with  obesity  and/or  diabetes
ellitus  and  exposure  to  benﬂuorex  for  a  mean  duration  of
2  ±  53  months.  Most  patients  had  symptomatic  heart  fail-
re.  Echocardiographic  analysis  also  identiﬁed  homogeneous
eatures  in  these  patients.  Common  ﬁndings  were  leaﬂet
hickening  and  retraction  with  inconstant  minimal  commis-
ural  fusion  and  rare  calciﬁcations.  Subvalvular  apparatus
as  thickened  and  shortened  with  fused  chordae  tendineae.
hese  injuries  resulted  mainly  in  loss  of  leaﬂet  coapta-
ion  and  predominant  mitral  or  aortic  regurgitation.  Indeed,
itral  and  aortic  regurgitations  were  the  most  frequent  fea-
ures,  whereas  signiﬁcant  stenoses  were  uncommon.  In  four
i
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ases  (10%),  organic  tricuspid  valve  involvement  was  also
dentiﬁed  and  there  was  one  case  of  organic  pulmonary  valve
ysfunction.  Multiple  ﬁbrotic  valve  diseases  were  present
n  more  than  75%  of  patients,  displaying  predominantly
n  association  of  aortic  and  mitral  regurgitations  (72.5%)
nd  leading  to  combined  valve  surgery  in  11  cases  (27.5%).
hese  morphological  and  histological  features  (valvular  tis-
ue  thickening  and  an  abundant  extracellular  matrix  of
lycosaminoglycans  and  collagen  with  proliferation  of  myo-
broblasts  and  smooth  muscle  cells)  were  similar  to  those
reviously  reported  after  exposure  to  other  appetite  sup-
ressants  and  ergot  alkaloids.
A  cohort  study  using  two  large  French  national  databases,
rawing  on  Health  Insurance  data  (Caisse  Nationale
’Assurance  Maladie  des  travailleurs  salariés  [CNAMTS])  and
iagnostic  data  on  discharge  from  public  and  private  hos-
italizations  (PMSI),  has  been  recently  published  [21].  Data
rom  patients  aged  40  to  69  years  with  reimbursements  for
ntidiabetic  drugs  in  2006  were  analysed.  The  risk  of  hospi-
alization  for  valvular  regurgitation  in  the  2  years  following
as  found  to  be  2.5  times  higher  when  taking  benﬂuorex  for
itral  regurgitation,  4.4  times  higher  for  aortic  insufﬁciency
nd  3.9  times  higher  for  valvular  replacement  surgery.  The
stimated  numbers  of  hospitalizations  for  a  diagnosis  of  VHD
as  found  to  be  5  for  10,000  patient-years.
The  re-evaluation  of  the  beneﬁt—risk  balance  of  ben-
uorex  in  light  of  these  data  led  to  suspension  of  the
arketing  authorization  of  the  drug  in  France  and  then
n  Europe,  in  November  and  December  2009,  respectively
22].
More  recently,  the  randomized  prospective  REGU-
ATE  trial  [23],  whose  results  were  published  in  2012,
ncluded  847  patients  with  type  II  diabetes  (mean  age:
9  years)  randomized  to  1  year  of  treatment  with  a
ombination  of  either  benﬂuorex—sulphonylurea  (n  =  423)
r  pioglitazone—sulphonylurea  (n  =  424).  Echocardiography
as  performed  at  baseline,  before  treatment,  and  at  1
ear  in  615  of  these  patients.  Emergence  (appearance
r  deterioration)  of  valvular  regurgitation  was  observed
ore  frequently  (27%  vs  11%;  P  <  0.0001)  in  the  group
reated  with  benﬂuorex  (OR  2.97  [1.91—4.63]).  At  last,  an
chocardiography-based  multicentre  study  [22]  compared
he  frequency  of  left  heart  valve  regurgitation  in  diabetic
atients  exposed  to  benﬂuorex  for  at  least  3  months  and  in
iabetic  controls  never  exposed  to  the  drug:  293  patients
nd  293  controls  were  matched  for  age,  gender,  body  mass
ndex,  smoking,  dyslipidaemia,  hypertension  and  coronary
rtery  disease.  The  frequency  and  relative  risk  (OR)  of  mild
r  more  severe  left  heart  valve  regurgitation  were  signiﬁ-
antly  increased  in  benﬂuorex-exposed  patients  compared
ith  controls:  31.0%  vs  12.9%  (OR  3.55  [2.03—6.21])  for
ortic  and/or  mitral  regurgitation;  19.8%  vs  4.7%  (OR  5.29
2.46—11.4])  for  aortic  regurgitation;  and  19.4%  vs  9.6%  (OR
.38  [1.27—4.45])  for  mitral  regurgitation.  This  study  there-
ore  conﬁrmed  that  the  use  of  benﬂuorex  is  associated  with
 signiﬁcant  increase  in  the  frequency  of  left  heart  valve
egurgitation  in  diabetic  patients.
Estimates  of  the  number  of  benﬂuorex-associated  deaths
n  France  have  been  proposed  as  probably  being  higher  than
00  [24]  and  were  more  recently  calculated  to  be  around
300  due  to  VHD  in  these  patients;  this  number  is  regarded
s  possibly  underestimated  [25].
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Valvular heart disease associated with
ergot-derived dopaminergic agonists
Two  drugs  of  this  pharmacological  class  are  implicated:  per-
golide  (Celance®)  and  cabergoline  (Dostinex®).  The  ﬁrst  drug
has  been  indicated  in  the  treatment  of  Parkinson’s  disease
(with  a  deﬁned  beneﬁt  against  bradykinesia  and  rigidity);
the  second  drug  is  also  used  as  an  antiparkinsonian  drug  in
many  countries  but  not  in  some  countries,  such  in  France,
where  it  is  only  used  to  treat  hyperprolactinaemic  disorders.
The  ﬁrst  three  case  reports  describing  a  probable  asso-
ciation  between  VHD  and  pergolide  were  published  in  2002
[26].  Subsequent  data  suggested  that  the  incidence  was  not
as  low  as  initially  believed.  Thus,  a  study  performed  in  Bel-
gium  [27]  evaluated  data  from  79  patients  treated  with
pergolide  and  19  patients  with  Parkinson’s  disease  who  had
never  been  treated  with  ergot-derived  dopaminergic  ago-
nists  (controls).  The  study  concluded  that  restrictive  VHD
was  present  in  33%  of  the  patients  treated  with  pergolide  and
in  none  of  the  controls.  The  VHD  was  more  frequently  mitral
regurgitation  and  more  rarely  aortic  or  tricuspid  regurgita-
tion.
Next,  two  studies  published  simultaneously  in  2007
clearly  conﬁrmed  the  increased  risk  of  VHD  with  pergolide
(as  well  as  cabergoline  when  used  to  treat  parkinsonian
patients)  [28,29].  The  ﬁrst  study  [28]  was  a  large  case-
control  analysis  nested  in  the  UK  GPRD  cohort  (already
used  to  evaluate  the  association  between  appetite  suppres-
sants  and  VHD,  as  previously  discussed).  The  cohort  selected
for  this  study  included  11,417  patients  who  had  received
antiparkinsonian  drugs  for  a  mean  duration  of  4.2  years.  In
this  cohort,  31  patients  were  newly  diagnosed  as  having  car-
diac  regurgitation.  Six  of  these  31  patients  were  treated  with
pergolide  and  six  with  cabergoline.  The  other  19  patients
did  not  receive  any  dopamine  agonist  during  the  year  pre-
ceding  the  diagnosis  of  valvular  disease.  These  31  patients
were  compared  with  663  age-  and  sex-matched  controls.  The
rate  of  newly  diagnosed  valve  regurgitation  was  multiplied
by  7.1  (95%  CI  2.3—22.3)  in  patients  treated  with  pergolide
and  by  4.9  (1.5—15.6)  in  patients  treated  with  cabergoline,
but  was  unchanged  in  patients  treated  with  other  dopamine
agonists  (lisuride,  pramipexole,  ropinirole).  In  this  study,
the  risk  was  further  raised  with  higher  doses  of  the  two
drugs.  These  results  were  conﬁrmed  by  the  second  study
[29],  in  which  the  echocardiographic  prevalence  of  VHD  was
studied  in  155  parkinsonian  patients  treated  with  dopamine
agonists  (64  received  pergolide,  49  received  cabergoline
and  42  received  non-ergot-derived  dopamine  agonists)  com-
pared  with  90  control  subjects.  Moderate  or  severe  valvular
regurgitation  was  found  with  a  greater  frequency  in  patients
treated  with  pergolide  (23.4%)  or  cabergoline  (28.6%)  than
in  patients  taking  non-ergot  dopamine  agonists  (0%)  or  in
controls  (5.6%).
Concordant  data  have  also  been  reported  in  France
[30,31].  The  ﬁrst  study  [30]  prospectively  included  86
parkinsonian  patients  treated  with  pergolide  for  more  than
3  months  compared  with  47  patients  not  treated  with  this
drug.  Moderate  to  severe  regurgitations  were  found  in  17.4%
of  patients  treated  with  pergolide  compared  with  only
4.3%  of  control  patients.  The  ﬁnding  of  regurgitation  was
found  to  be  related  to  the  cumulative  dose  of  pergolide.  A
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eta-analysis  was  then  performed  on  seven  comparative
rials  and  reported  an  odds  ratio  of  3.1,  the  risk  being  sta-
istically  correlated  with  the  pergolide  cumulative  dose.
n  another  study  [31],  30  patients  with  Parkinson’s  disease
reated  by  pergolide  were  evaluated  and  compared  with  a
ontrol  group  (age-  and  sex-matched  consecutive  patients
ithout  known  VHD  referred  to  the  cardiology  department
or  various  reasons).  A  restrictive  pattern  of  valvular  regur-
itation  was  observed  in  12/30  (40%)  parkinsonian  patients
reated  with  pergolide,  with  heart  failure  symptoms  in  two
ases.  Compared  with  controls,  aortic  and  mitral  regur-
itation  occurred  respectively  3.1  and  10.7  times  more
requently  under  pergolide  treatment.  An  increase  in  the
requency  of  tricuspid  regurgitation  was  also  found  but  this
as  not  signiﬁcant.  In  10  of  the  13  patients  presenting  valvu-
ar  regurgitation,  pergolide  treatment  was  withdrawn.  In  six
f  these  patients,  the  mitral  regurgitation  grade  was  found
o  be  lower  10  to  18  months  later,  whereas  no  change  was
bserved  for  aortic  regurgitation.
From  the  data  available  in  the  literature,  VHD  associated
ith  pergolide  is  generally  plurivalvular,  involving  mitral
alves  slightly  more  frequently  (and  then  aortic  and  tricus-
id  valves).  Echocardiographic  and  histopathological  lesions
ere  found  to  be  similar  to  those  described  in  VHD  due  to
xposure  to  appetite  suppressants.
These  data  led  the  FDA  to  withdraw  pergolide  from  the
arket  in  the  USA.  In  many  other  countries,  especially  in
urope,  pergolide  continued  to  be  marketed  because  the
rug  was  considered  potentially  to  have  a speciﬁc  place  in
he  management  of  Parkinson’s  disease.  However,  signiﬁ-
ant  limitations  in  the  use  of  the  drug  were  announced:
se  limited  to  patients  with  parkinsonian  symptoms  resistant
o  other  dopamine  agonists;  echocardiography  performed
efore  drug  initiation  and  then  every  6  months;  and  con-
raindication  in  case  of  previous  VHD  or  ﬁbrosis.  With  these
imitations,  prescription  of  pergolide  largely  decreased  and
o  more  VHDs  associated  with  pergolide  were  notiﬁed.  The
arketing  of  this  drug  ﬁnally  stopped  in  France  in  May  2011.
alvular heart disease associated with
abergoline when treating
yperprolactinaemic disorders
abergoline,  an  ergot-derived  dopamine  agonist  reported  as
eing  associated  with  VHD  when  used  in  Parkinson’s  disease,
s  also  commonly  used  as  ﬁrst-line  therapy  in  hyperprolacti-
aemia  patients,  as  it  is  able  to  normalize  prolactin  levels
nd  to  restore  gonadal  function  and  prolactinoma  size  when
dministered  at  low  doses  (0.5—2  mg/week)  [32].
Very  few  case  reports  have  been  published  on  VHD
ssociated  with  the  intake  of  low  doses  of  cabergoline  to
reat  hyperprolactinaemia  [33,34].  In  one  of  these  cases,
 10-year  previous  intake  of  dexfenﬂuramine  and  then
romocriptine  may  also  be  implicated.
Several  pharmacoepidemiological  studies  have  been  per-
ormed  to  evaluate  the  valvular  risk  of  long-term  low  doses
f  cabergoline  used  to  treat  hyperprolactinaemic  disorders;
ost  were  unable  to  conﬁrm  the  risk  of  valvular  regurgita-
ion.  However,  two  studies  found  an  increased  prevalence  of
ild  tricuspid  regurgitation  [35,36].  The  clinical  signiﬁcance
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f  the  data  available  needs  to  be  conﬁrmed  by  larger
rospective  studies  with  rigorous  methodology  and  pro-
onged  duration  of  follow-up  [37].
alvular heart disease associated with
cstasy (MDMA)
DMA  (also  known  as  ecstasy)  is  used  as  a  recreational
rug  (psychoactive  stimulant).  In  2007,  Droogmans  et  al.
eported  that  this  drug  was  associated  with  the  develop-
ent  of  signiﬁcant  valvular  regurgitation  in  long-term  users
3—6  tablets/week  for  6  years)  with  a  signiﬁcant  correla-
ion  between  dose  and  severity  of  the  valvular  alterations,
hich  were  very  similar  to  those  reported  with  pergolide
nd  fenﬂuramine  [38].
echanisms involved in drug-induced VHD
he  hypothesis  of  a  serotoninergic  mechanism  to  explain
rug-induced  VHD  has  been  postulated  since  the  ﬁrst  cases
ere  reported  because  of  their  similarities  to  carcinoid
eart  disease.  Serotonin  is  known  to  have  mitogenic  effects
n  ﬁbroblasts  and  smooth  muscle  cells  by  upregulating
ransforming  growth  factor  beta,  which,  in  turn,  stimulates
lycosaminoglycan  production  and  cell  proliferation.  It  was
nitially  postulated  that  appetite  suppressants,  such  as  fen-
uramine,  increase  circulating  serotonin  concentrations  by
nterfering  with  serotonin  transporter  proteins  [1]. How-
ver,  it  has  been  shown  that  chronic  fenﬂuramine  use  lowers
lasma  and  platelet  serotonin  concentrations.  It  was  there-
ore  hypothesized  that  drug-induced  VHD  may  be  related  to
he  stimulation  of  a  serotonin  receptor  subtype.  A  role  for
HT2B receptors,  a  subtype  of  one  of  the  seven  serotonin
5HT)  receptors,  has  been  demonstrated  (Fig.  3).  Indeed,
ethylergonovine  (an  active  metabolite  of  ergotamine  and
ethysergide)  and  pergolide  have  high  afﬁnity  for  5HT2B
eceptors.  Pergolide,  cabergoline  and  MDMA  are  also  potent
gonists  at  the  5HT2B receptor.  It  has  been  highlighted
hat  lisuride,  an  ergot-derived  dopaminergic  agonist  like
ergolide,  does  not  induce  VHD.  Actually,  lisuride  is  char-
cterized  by  an  antagonistic  (and  not  agonistic)  effect  on
HT2B receptors  [39].  Norfenﬂuramine  (a  metabolite  of  fen-
uramine),  dexfenﬂuramine  and  benﬂuorex  have  also  been
ound  to  have  a  high  afﬁnity  for  5HT2B receptors  [40].
Serotonin  5HT2B receptors  are  expressed  on  both  aortic
nd  mitral  valve  leaﬂets  (as  well  as  in  pulmonary  arter-
es);  their  stimulation  by  5HT2B agonist  drugs  may  result
n  ﬁbroblast  proliferation  and  collagen  synthesis,  and  may
xplain  the  development  of  VHD.  These  lesions  can  occur
n  bioprostheses,  as  reported  recently  in  a  patient  with
imilar  ﬁbrotic  histopathological  alterations  occurring  simul-
aneously  on  the  mitral  bioprosthesis  and  the  native  aortic
alve  during  benﬂuorex  therapy  [41].
Recently,  a  model  of  VHD  has  been  reported  in  Wistar  rats
xposed  over  5  months  to  pergolide  or  serotonin;  the  rats
eveloped  valvular  lesions  very  similar  to  those  described
n  human  pathology,  with  the  same  echocardiographic  and
istological  features.  The  use  of  cyproheptadine,  a  5HT2B
ntagonist  drug,  prevented  the  development  of  pergolide-
nduced  VHD  in  this  model  [42].  Such  a  model,  as  well  as  theigure 3. Mechanisms of drug-induced valvular heart disease.
GF: transforming growth factor beta.
earch  for  5HT2B activity,  may  provide  future  tools  that  will
robably  be  useful  in  evaluating  the  cardiac  safety  of  new
rugs  as  well  as  the  evidence  of  5HT2B receptor  agonistic
otency  in  pharmacological  in  vitro  assays  [43].
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